Related Experiment Video
Updated: Jan 15, 2026
08:48
Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
4.8K
Research Progress on Idebenone in Neurodegenerative Diseases
Yanqing Zhang1, Yanhong Ren1, Xiaoran Zhu1
1Department of Neurology The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital) Jinan Shandong China.
Aging Medicine (Milton (N.S.W))
|January 14, 2026
Summary
Idebenone (IDE), a Coenzyme Q10 analogue, shows promise for treating neurodegenerative diseases by protecting brain cells and improving energy production. Further research supports its potential to slow disease progression.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Neurodegenerative diseases (NDs) represent a significant health challenge.
- Idebenone (IDE), a synthetic Coenzyme Q10 analogue, has emerged as a potential therapeutic agent.
- Understanding IDE's mechanisms is crucial for developing effective ND treatments.
Purpose of the Study:
- To review the pharmacological properties and therapeutic potential of idebenone (IDE) in neurodegenerative diseases.
- To elucidate IDE's neuroprotective mechanisms and evaluate its clinical applications.
- To discuss the translational potential of IDE in treating conditions like Alzheimer's and Parkinson's disease.
Main Methods:
- Comprehensive literature review of pharmacological and clinical studies on idebenone.
- Analysis of idebenone's mechanisms, including antioxidant and mitochondrial effects.
- Evaluation of current clinical research findings and translational potential.
Main Results:
- Idebenone exhibits potent antioxidant activity, reducing reactive oxygen species.
- IDE enhances mitochondrial bioenergetics and regulates cellular metabolism.
- Clinical evidence suggests IDE can mitigate symptoms and modify disease progression in NDs.
Conclusions:
- Idebenone is a promising mitochondrial-targeted agent for neurodegenerative diseases.
- IDE demonstrates multifaceted neuroprotective effects.
- Further research and clinical trials are warranted to optimize IDE-based interventions for NDs.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
552
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
552
01:24Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K